Literature DB >> 16724055

Hypoxia signalling in cancer and approaches to enforce tumour regression.

Jacques Pouysségur1, Frédéric Dayan, Nathalie M Mazure.   

Abstract

Tumour cells emerge as a result of genetic alteration of signal circuitries promoting cell growth and survival, whereas their expansion relies on nutrient supply. Oxygen limitation is central in controlling neovascularization, glucose metabolism, survival and tumour spread. This pleiotropic action is orchestrated by hypoxia-inducible factor (HIF), which is a master transcriptional factor in nutrient stress signalling. Understanding the role of HIF in intracellular pH (pH(i)) regulation, metabolism, cell invasion, autophagy and cell death is crucial for developing novel anticancer therapies. There are new approaches to enforce necrotic cell death and tumour regression by targeting tumour metabolism and pH(i)-control systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724055     DOI: 10.1038/nature04871

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  624 in total

Review 1.  Adipose tissue remodeling and obesity.

Authors:  Kai Sun; Christine M Kusminski; Philipp E Scherer
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

2.  Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.

Authors:  Tsuyoshi Osawa; Masashi Muramatsu; Feng Wang; Rika Tsuchida; Tatsuhiko Kodama; Takashi Minami; Masabumi Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

4.  Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Authors:  Charline Ladroue; David Hoogewijs; Sophie Gad; Romain Carcenac; Federica Storti; Michel Barrois; Anne-Paule Gimenez-Roqueplo; Michel Leporrier; Nicole Casadevall; Olivier Hermine; Jean-Jacques Kiladjian; André Baruchel; Fadi Fakhoury; Brigitte Bressac-de Paillerets; Jean Feunteun; Nathalie Mazure; Jacques Pouysségur; Roland H Wenger; Stéphane Richard; Betty Gardie
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

5.  CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.

Authors:  Renaud Le Floch; Johanna Chiche; Ibtissam Marchiq; Tanesha Naiken; Tanesha Naïken; Karine Ilc; Karine Ilk; Clare M Murray; Susan E Critchlow; Danièle Roux; Marie-Pierre Simon; Jacques Pouysségur
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 6.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

7.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

8.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 9.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 10.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.